GlaxoSmithKline Racing to Provide Only Effective Covid-19 Antibody Treatment

GlaxoSmithKline PLC and partner Vir Biotechnology Inc. are straining to meet soaring demand for their Covid-19 antibody treatment after the highly mutated Omicron variant knocked out the two competing products. Demand has jumped in recent weeks for the treatment, called sotrovimab, because it is the only antibody drug authorized in the U.S. for the newly infected that has been found to work against Omicron. Glaxo and Vir, which were using one manufacturing plant, say they have raced to add another and taken other steps to roughly double the number of doses they can deliver to the U.S. in the first quarter to 600,000.